garenoxacin has been researched along with piroxicam in 1 studies
| Studies (garenoxacin) | Trials (garenoxacin) | Recent Studies (post-2010) (garenoxacin) | Studies (piroxicam) | Trials (piroxicam) | Recent Studies (post-2010) (piroxicam) |
|---|---|---|---|---|---|
| 195 | 19 | 46 | 3,084 | 796 | 704 |
| Protein | Taxonomy | garenoxacin (IC50) | piroxicam (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.3043 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.1 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
1 other study(ies) available for garenoxacin and piroxicam
| Article | Year |
|---|---|
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |